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Narcolepsy, a chronic disorder of the sleep–wake cycle of multifactorial etiology, is character-
ized by excessive daytime sleepiness, often associated with cataplexy, hypnagogic/hypno-
pompic hallucinations and sleep paralysis. Both early clinical suspicion and therapeutic
approach are essential for promotion of cognitive development and social integration of these
children. The authors present a descriptive retrospective study of a series of eight children in
whom symptoms ﬁrst started between 6.8 and 10.5 years of age. Diagnostic delay ranged from
4 months to 2 years. One child had H1N1 ﬂu vaccination eight months before the clinical
onset. The ﬁrst multiple sleep latency test was positive in 6 of 8 cases. All cases were treated
with methylphenidate, and venlafaxine was associated in 4 of them. In one case the initial
therapy was exclusively behavioral. In all cases, symptomatic improvement, better school
performance and social integration were achieved after therapeutic adjustment.
& 2014 Brazilian Association of Sleep. Production and Hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Narcolepsy is a chronic disorder of the central nervous
system (CNS) in which there is a disturbance of the regulation
of the sleep–wake cycle, with intrusion of REM sleep during
periods of the wake state, whose paradigmatic manifestation
is cataplexy. Narcolepsy with cataplexy (NC) has a prevalence
of 0.02–0.05% in various Caucasian groups [1–4] and a higher
value among the Japanese population (0.16%) [2,3]. The
prevalence of narcolepsy without cataplexy is unknown [3].ep. Production and Hosti
licenses/by-nc-nd/3.0/).
ital, Hospital and Univer
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an Association of SleepWith a peak onset during the second decade of life [2], the
initial symptoms are revealed by an excessive daytime
sleepiness (EDS) that is later and often associated with
cataplexy, hypnagogic/hypnopompic hallucinations and
sleep paralysis. Nocturnal sleep disturbance is often also
associated, being sometimes interpreted as insomnia [2].
Initially considered a family disease, recent studies have
pointed out to a sporadic disease, although with a strong genetic
susceptibility [3] marked by the presence of the allele HLA
DQB1*06:02. The autoimmune destruction of hypothalamicng by Elsevier B.V. This is an open access article under the CC BY-
sity Center of Coimbra, Av. Afonso Romão. 3000-602, Coimbra,
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ibility has been signaled as the most likely etiological hypothesis
[3,5]. Hypocretin plays a key role in regulating the sleep–wake
cycle since its decrease leads to a loss of the boundaries between
awake, asleep or dreaming states [2]. It is believed that environ-
mental factors such as bacterial (namely streptococcus [3]) or
viral infections and some vaccines, might have a triggering role
in this process [6–8]. After the ﬂu pandemic caused by the H1N1
inﬂuenza virus, namely between September 2009 and August
2010, an increased incidence of this disease was observed
especially among the northern European and American coun-
tries [9,10]. The disease was much more common after the
administration of the vaccine containing the adjuvant ASO3 [11]
(onset from 2 weeks to several months) compared to the
incidence after the infection by the virus H1N1 itself [3].
The different sleep duration in children, their reactions and
difﬁculty in verbalizing their symptoms make it even more
difﬁcult to recognize and value the clinical data at these ages.
Excessive sleepiness might be interpreted as a physiological
need of napping in a small child, and in turn as a manifesta-
tion of laziness in older children. In addition to the excessive
sleepiness, memory lapses, concentration problems and auto-
matic behaviors, especially during monotonous activities, are
also associated and can result in learning disabilities at school
age [1,2,5,12,13]. Repeated difﬁculty in achieving expected or
desired levels of performance might lead to irritability, hyper-
activity, aggressiveness or even depression [2].
The hypnagogic or hypnopompic hallucinations sometimes
associated with sleep paralysis, might be scary to the child,
leading to resistance in going to sleep or be interpreted as
nightmares or night terrors. Cataplexy is a sudden and rever-
sible reduction in muscle tone, commonly triggered by a
stimulus such as laughter, surprise or fright. It may lead to
falls, which in small children may not be taken into considera-
tion and/or be misinterpreted as a simple clumsy gait, or lead to
differential diagnosis with atonic convulsive crisis [2,14] or
cardiovascular syncope. In children, cataplexy might be limited
to facial muscles, giving rise to an apathetic face, open mouth
and protruding tongue, with a slow and slurred speech.
Other symptoms that may be associated are obesity and early
puberty [13,15]. The weight increase might be related to noctur-
nal sleep disturbance and consequent change of the feeding
pattern [16,17], or with the fact that hypocretin deﬁciency may
have a direct effect onmetabolism and lower the basal metabolic
needs [5].
The lack of symptom speciﬁcity and the other mentioned
difﬁculties make diagnosis of narcolepsy in children a real
challenge. Sometimes other diagnosis such as attention
deﬁcit hyperactivity disorder, epilepsy, behavioral insomnia,
depression or other psychiatric disturbance may be evoked.
Therefore, diagnosis may suffer signiﬁcant delays and it is
often only achieved in adolescence or early adulthood. Delays
of 10–15 years between clinical presentation and diagnostic
conﬁrmation have been described [1,6].
In the pediatric population and in cases of sudden onset or
less characteristic evolution, it is important to exclude secondary
causes of narcolepsy. Thesemay amount up to 25%, with genetic
syndromes and hereditary metabolic diseases being the most
predominant causes [10]. In these cases, the symptoms appear at
an early age and associated with the underlying pathology[1,6,18]. Cataplexy is highly selective and almost pathognomonic
of narcolepsy, but it also constitutes one of the symptoms to be
considered in some genetic diseases, such as Niemann-Pick type
3, Norrie and Prader-Willi syndromes, myotonic dystrophy type
1, or in CNS trauma and tumors [2,10]. In narcolepsy, cataplexy
often appears months or years after EDS; if it appears isolated or
at an early age, the hypothesis of hypothalamic lesion must be
considered [2].
The diagnosis is based on the results of polygraphic sleep
study (PSG) and on the multiple sleep latency test (MSLT).
However, in children, caution should be taken in MSLT inter-
pretation due to the difﬁculty in establishing the lower age limit
for application of the diagnostic criteria. Previously, the lower
age limit has been established at 8 years age [6,11], but recent
studies point to the possibility of its application since 5 years of
age in cases with a strong suspicion of narcolepsy [19]. The
MSLT is considered positive if the average sleep latency is less
than 8min and if there is presence of at least 2 sleep onset
rapid eye movement periods (SOREMPs) [19]. PSG must be made
the night before the MSLT in order to exclude the existence of
another pathology, such as an obstructive sleep apnea syn-
drome, which might justify the EDS.
HLA DQB1*06:02 is the marker with highest speciﬁcity for
narcolepsy in all ethnic groups [3], and this relation is
particularly strong in the cases where cataplexy is present
[3]. This allele is present in 90% of the narcolepsy cases, but it
is also present in 12–38% of people without the disease [3,11].
The dosage of hypocretin-1 in the cerebrospinal ﬂuid (CSF)
can be useful in complex cases or where there is difﬁculty in
interpreting the results of exams [14]. Its use is not wide-
spread, since it is hardly available and also because it needs
an invasive technique.
The therapeutic approach includes both behavioral and
pharmacological therapy in order to control the symptoms.
Some drugs used in adulthood are not yet approved for
children (e.g. modaﬁnil) or are poorly studied in children (e.
g. sodium oxybate and immunosuppressant treatment) [2].
The therapeutic monitoring is usually based on clinic symp-
toms; however, some centers use the Maintenance of Wake-
fulness Test [20].2. Material and methods
A retrospective and descriptive analysis of the ﬁles of children
and teenagers with narcolepsy, diagnosed and followed
between 1994 and 2013 at a tertiary pediatric hospital, was
performed. Clinical data and all complementary exams were
collected. All the children underwent PSG and MSLT. For sleep
stages and respiratory classiﬁcation, we used the Rechtschaf-
fen and Kales rules until 2007, and then after, the American
Academy of Sleep Medicine's classiﬁcation was used. In the PSG,
the leg movement index referred to the number of leg move-
ments, regardless of their characteristics, per hour of sleep.
MSLT was considered compatible with narcolepsy when the
average sleep latency was less than 8 min and when at least 2
SOREMPs were present during the nap time. Hypocretin level
below 110 pg/ml was considered a low value [21].
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The sample consisted of 8 Caucasian children (5 boys). The
ﬁrst symptoms occurred between the ages of 6 and 10 years
(median – 8 years). The diagnostic delay (period of time
between the onset of symptoms and the diagnostic conﬁrma-
tion by complementary exams) ranged from 4 to 24 months
(median – 14 months) (Table 1).
On clinical presentation, all of them had EDS, characterized
by the reappearance of naps and frequent episodes of sleepiness
in both monotonous situations (car traveling, watching televi-
sion) and during active tasks (talking, eating). In one case, there
were also, since the beginning, suggestive symptoms of cata-
plexy (jaw fall and hypotony of the limbs triggered by laughter)
and hypnagogic and hypnopompic hallucinations. During the
clinical evolution, symptoms of partial (loss of the cervical tonus
or jaw fall with protrusion of the tongue) or complete cataplexy
(hypotony of the limbs and fall) appeared in 4 more cases, as
well as hypnagogic hallucinations in 2 cases and sleep paralysis
in a single case. There was impact on school performance in 5
cases and psychosocial difﬁculties in 3 of them. At the ﬁrst
consultation, all children showed body mass index (BMI) Z75th
percentile, 5 were overweight (85th percentileoBMIo95th per-
centile) and 1 had obesity (BMI Z95th percentile). During the
evolution, there was a trend for BMI increasing in 4 cases.
In one case, the anti-inﬂuenza H1N1 vaccine (adjuvant
SO3) had been administered 8 months before the onset of the
symptoms. In 2 of the 8 cases, there was a family record of
severe EDS in 1st and 2nd degree relatives with no clear
diagnosis.
All children performed PSG with MSLT shortly after diag-
nostic suspicion (between 7 and 11 years old) – Table 2. In PSG,
sleep efﬁciency below 80% was recorded in 5 patients and the
microarousal index ranged between 2.6 and 6.7. Regarding the
respiratory parameters, one of the 8 patients snored, the apnea–
hypopnea index was always less than 1 and there was no
desaturation. The MSLT showed average sleep latencies
between 0.1 and 8.5min, average REM sleep latencies between
1.37 and 4.83min and 2–4 SOREMPs. The ﬁrst MSLT was
compatible with the diagnosis of narcolepsy in 6 of the 8 cases,
while a second test was necessary in the other 2. During the
initial MSLTs, these 2 children only slept one nap; one did not
have REM sleep and the other had only one SOREMP.
The allele HLA DQB1*06:02 was present in all cases and it
was associated with the concomitant presence of allele HLA
DRB1*15 in 7 cases. In the 6 most recent cases, we determined
the anti-streptolysin-O levels and a high level (324 UI/ml) was
present in only one of them.
In one case, due to the diagnostic complexity, hypocretin-
1 evaluation in CSF was performed, and its value was low
(70 pg/ml).
All children had already been observed in other consulta-
tions, where CNS imaging examinations (6) and EEG (6) had
been performed.
Both behavioral therapy and nutritional counseling were
established in all cases. Behavioral therapy (structured plan
with schedule of nocturnal sleep and naps) was used alone at
an initial stage of the ﬁrst case. Regarding pharmacological
approach, they were all medicated with methylphenidate. In4 cases, it was associated with venlafaxine for cataplexy
management. The drug dosage was adjusted according to
the clinical situation. In the 4 cases with low ferritin level,
iron supplementation was prescribed.
In 6 cases, there was a continuous follow-up by the Sleep
Psychology Consultation Group and, in two 12 years-old
teenagers, it was necessary to add psychiatric support due
to behavioral problems and depressive symptomatology. In
all cases there was an improvement in school performance
and social integration skills.4. Discussion
The analyzed group of children presents several similarities
with the data that have been published in the literature
[10,17]. The ﬁrst symptom in all children was EDS. The
reduced initial presence of cataplexy, hallucinations and
sleep paralysis may be due to the children's difﬁculty in
reporting information, as described by other authors [14]. The
diagnosis delay ranged from 4 to 24 months with a median of
14 months, which represents a lower value than the ones
reported by other authors [10,17]. This may be explained by
the awareness of the local medical community for sleep
disturbances due to the presence of a children's hospital
specialized in sleep disorders in the region.
In one quarter of the patients there were 1st and 2nd
degree family members with EDS, and although no clear
diagnosis was available, there was a case with enough
severity to have a fatal outcome while driving. The familial
clustering has already been described, with about 8–10% of
the patients referring the existence of a relative with narco-
lepsy/cataplexy or with EDS [3]. First degree family members
have a risk of 0.9–2.3% for disease, which, albeit low, repre-
sents a 40 times higher risk in comparison with the general
population [22,23].
The etiology was considered idiopathic in all cases, based
on the high number of complementary exams performed. In
the 6 cases in whom the anti-streptolysin-O levels was
obtained, only one demonstrated a mildly high level, which
does not support the hypothesis of streptococcal infection as
a main triggering factor. In the case where the anti-inﬂuenza
H1N1 vaccination was performed, we can only wonder about
its inﬂuence since it is not possible to conclude about a
correlation favoring a cause and effect relationship [24].
During consultation, all children had BMI Z75th percen-
tile and, despite nutritional advice, there was still a further
50% increase afterwards. The prevalence of obesity/weight
gain was similar to the one described by Poli [15], although
his study refers only to patients with NC. However, unlike the
mentioned study, our work did not show more early-onset
weight gain among the patients with NC, which may be due
to the small size of the sample. The connection between an
increased weight gain and the onset of cataplexy described by
Nevsimalova [13] was also veriﬁed in our sample.
The sleep study (PSG and MSLT) is crucial for diagnosis
and, in doubtful cases, it should be repeated in the presence
of a suggestive clinical picture and once other etiologies have
been excluded. In 2 of the cases, the initial MSLT was
negative, but the diagnostic hypothesis led to its repetition
Table 1 – Clinical characterization and treatment of children with narcolepsy.
Number,
gender
Age at ﬁrst
symptoms (years)
Age at Ds (years)/Ds
delay (months)
Age at onset (years) Nocturnal sleep
disturbance
HLA test Initial/
posterior
BMI
Treatment
after Ds
Sleepiness Cataplexy Hallucinations Sleep
paralysis
1, F 7 9/24 7 11 17 – No DQB1n06:02/
DRBn15
P90–95/P90–
95
M
2, F 9 10/8 9 9 9 – Yes DQB1n06:02/
DRBn15
P90–95/P95–
97
MþV
3, M 8 8/4 8 8 – 9 Yes DQB1n06:02/
DRBn15
P90–95/P97 MþV
4, M 6 8/14 6 – – – No DQB1n06:02/
DRBn15
P85–90/P75–
85
M
5, M 10 11/9 10 11 – – Yes DQB1n06:02/
DRBn15
P95–97/
P497
MþV
6, F 6 9/24 6 – 9 – Yes DQB1n06:02/
DRBn15
P75/P25–50 M
7, M 10 11/15 10 – – – Yes DQB1n06:02 P85–90/P75–
85
M
8, M 7 9/24 7 9 – – Yes DQB1n06:02/
DRBn15
P75–85/P85 MþV
Total
(median)
6–10 (8) 8–11 (9)/4–24(14) 6–10 (8) 8–11 (9) 9–17 (9)
Ds – diagnosis; BMI – Body Mass Index; M – Methylphenidate; V – Venlafaxine.
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Table 2 – Characteristics of polygraphic sleep studies and multiple sleep latency tests.
Number,
gender
TST (min) Polygraphic sleep study Multiple sleep latency test
Efﬁciency
(%)
Arousal
index
Mean SpO2
(%)
Mean sleep latency
(min)
SOREMP Mean REM latency
(min)
1, F 385 99 ND 96 0.1 2 1.5
2, F 330 76 3.4 94 1.7 4 3.8
3, M 358 66.7 6.7 98 1 3 2
4, M 365 62 2.6 99 8.5 3 4.83
5, M 433 72 9 99 5.2 4 2
6, F 401 81.9 6.1 99 2.37 3 1.67
7, M 438 79.8 5.1 98 2.25 4 1.37
8, M 432 84.7 3.8 98 2.62 4 1.37
Total
(median)
330–438
(393)
62–99
(77.9)
2.6-6.7 (5.1) 94–99 (98) 0.1–8.5 (2.3) 2–4 (3.5) 1.37–4.83 (1.83)
TST – Total sleep time; SOREMP – sleep onset rapid eye movement period; ND – data not available.
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these cases, symptoms were so suggestive and disturbing,
that the therapy was initiated despite the ﬁrst MSLT non-
conclusive result.
The presence of the allele HLA DQB1*06:02 was veriﬁed in
all cases, conﬁrming the strong association with narcolepsy
described for this allele [2,3,24,25], especially when cataplexy
is present. About 99% of the patients with NC are HLA
DQB1*06:02 positive. Moreover, we conﬁrmed 7 positive HLA
DRB1*15 cases. The association of these 2 alleles is present in
75–90% of the Caucasian NC [1,6] and it increases the prob-
ability of severe EDS [6]. Three of the cases of our series did
not have cataplexy, but it may still manifest itself in the
future, as it is a symptom that appears within months to
several years after EDS [13].
The hypocretin-1 dosage in the CSF, whose availability is
recent in our country, was performed only in one case, and
the result was low. Low or undetectable values are usually
found in patients with NC [6] or may even precede the onset
of cataplexy [13]. Its dosage may be useful in some difﬁcult
cases, such as when the MSLT is inconclusive [14].
The medication used is mainly directed to EDS and
cataplexy. Currently, one of the ﬁrst-line treatments of EDS
in adults with narcolepsy is modaﬁnil. Its usage in children
seems to be safe (though few studies were performed) [10] but
it is not approved yet and so it is scarcely used. In all cases,
we used methylphenidate and, in 4 of them, venlafaxine was
associated for cataplexy control, with a good response. The
gradual increase of dosage was determined by the clinical
responses. Sodium oxybate, used for the simultaneous con-
trol of EDS and cataplexy, is not available in our country yet.
Proper education about the disease is essential, not only
for children but also for their educators. This education must
be extended also to school, since narcolepsy may have
important consequences upon learning performance and
social integration. The guidance by the Sleep Psychology
Consultation Group proved to be very important in chronic
diseases management for both children/teenagers and their
parents. It allowed for early identiﬁcation of behavioral
changes observed in 3 of the cases.Narcolepsy in children is rare and it is one of the most often
underdiagnosed diseases [13]. Excessive Daytime Sleepiness is
commonly the initial symptom of the disorder and may remain
isolated for a long time, although with developmental repercus-
sions. Decreasing diagnostic delay is a primary target for
psychosomatic morbidity reduction. A family physician may
work his whole life without seeing a single case of narcolepsy
and even less in a child. It seems important to increase the
awareness of health and educational professional communities
for this disease.
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